SecBot SecBot
PRESS-RELEASE ·Filed Apr 14, 2026

LGND

Ligand Pharmaceuticals
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Traders should monitor FILSPARI's commercial uptake in FSGS, as the expanded indication significantly increases the addressable market and royalty stream for Ligand; the 9% royalty on a growing sales base could drive outsized revenue growth if adoption accelerates.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$232.34
T+0 close · Apr 14, 2026 · via day close
Latest settled
+38.85%
T+60 · $322.61
Vs SPY
+30.33%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 14 $232.34entry
  2. T+1 · 7mo ago −3.12%α −3.90% · $225.09
  3. T+5 · 7mo ago −2.44%α −3.83% · $226.67
  4. T+20 · 6mo ago −5.10%α −11.40% · $220.48
  5. T+60 · 4mo ago +38.85%α +30.33% · $322.61
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ligand Pharmaceuticals announced FDA approval for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS), a rare kidney disorder, marking the first approved therapy for this condition. Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI, which expands its commercial potential beyond IgA nephropathy and positions it as a key driver of future royalty growth.

Key Facts

  • FDA approved FILSPARI for FSGS in patients aged 8+ without nephrotic syndrome, the first and only approved treatment for this indication.
  • Ligand receives a 9% royalty on worldwide net sales of FILSPARI, which is already the most prescribed FDA-approved drug for IgA nephropathy.
  • Phase 3 DUPLEX study showed a 46% reduction in proteinuria overall and 48% in non-nephrotic syndrome patients, with statistically significant results.
  • Addressable U.S. population estimated at over 30,000 patients with FSGS without nephrotic syndrome.
  • FILSPARI has a dual mechanism targeting endothelin A and angiotensin II receptors, offering kidney protection.

Financial Impact

High incremental royalty revenue potential from expanded indication; FILSPARI now addresses a second rare kidney disease with significant unmet need.

royalty revenuelong-term revenue growthmarket expansion

Risk Factors

  • Commercial execution risk: Market penetration and reimbursement for the new FSGS indication may lag expectations.
  • Regulatory and clinical risk: Future safety findings or label restrictions could limit use.
  • Competition risk: Emerging therapies for FSGS could challenge FILSPARI's dominance.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3273192

US Market Status

Market Closed · Opens Wed (10h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 14, 2026